Prednisolone Dosing in Nephrotic Syndrome
For children with first-episode nephrotic syndrome, use prednisolone 60 mg/m²/day (maximum 80 mg) for 4-6 weeks daily, followed by 40 mg/m²/day on alternate days for 4-6 weeks, for a total treatment duration of 8-12 weeks. 1, 2, 3
First Episode Treatment
The KDIGO 2021 and 2025 guidelines establish clear dosing parameters:
- Daily phase: 60 mg/m²/day (maximum 80 mg) for 4-6 weeks
- Alternate-day phase: 40 mg/m²/day for 4-6 weeks
- Total duration: 8-12 weeks of therapy 1, 2
The FDA label confirms the standard regimen of 60 mg/m²/day in three divided doses for 4 weeks, followed by single-dose alternate-day therapy at 40 mg/m²/day for 4 weeks 3. However, single daily dosing is preferable to divided dosing as it causes less hypothalamic-pituitary-adrenal (HPA) axis suppression and may prolong time to first relapse 4.
Dosing Method: BSA vs Weight-Based
Body surface area (BSA)-based dosing (40-60 mg/m²) is superior to weight-based dosing (1.5-2 mg/kg). Weight-based dosing can result in relative underdosing in smaller children, which increases the risk of frequent relapses 5. The evidence shows that children dosed by weight rather than BSA had a 16.6% underdosing rate in frequent relapsers versus 8.7% in infrequent relapsers (P = 0.03) 5.
Critical caveat: Age at onset and cumulative prednisolone dose are the strongest predictors of disease course. Children ≥ 2.5 years old and those receiving cumulative doses ≥ 3.135 g/m² have significantly reduced risk of frequent relapses 6. This underscores the importance of adequate initial dosing.
Relapse Treatment
For relapses in steroid-sensitive nephrotic syndrome:
- Standard approach: 2 mg/kg/day (or 60 mg/m²/day) until remission (typically 3 consecutive days without proteinuria)
- Then: 1.5 mg/kg or 40 mg/m² on alternate days for 4 weeks 3, 7
Emerging evidence supports lower-dose regimens for selected patients. In children with infrequently relapsing disease without glucocorticoid toxicity, doses of 1-1.5 mg/kg/day may achieve remission with significantly lower cumulative steroid exposure 8, 7. One study showed 1.5 mg/kg/day achieved remission in 10.2 days versus 7.2 days with 2 mg/kg/day, with only 2 of 20 patients failing to respond 8.
However, use standard dosing (2 mg/kg/day) for:
- First relapse
- Frequently relapsing patients
- Steroid-dependent patients
- Any patient with glucocorticoid toxicity requiring robust treatment
Frequently Relapsing and Steroid-Dependent Disease
The 2025 KDIGO guideline made a critical change: Daily glucocorticoids should NOT be routinely given during upper respiratory tract infections to prevent relapses 2. The PREDNOS2 study demonstrated no difference in infection-associated relapses between prednisolone and placebo.
For prevention of relapses in frequently relapsing disease without glucocorticoid toxicity, low-dose alternate-day prednisolone may be considered before introducing glucocorticoid-sparing agents 2.
For children with serious glucocorticoid-related adverse effects or all children with steroid-dependent nephrotic syndrome, glucocorticoid-sparing agents (calcineurin inhibitors, cyclophosphamide, levamisole, mycophenolate mofetil, or rituximab) should be prescribed rather than continuing glucocorticoids alone 2.
Key Pitfalls to Avoid
Underdosing young children: Always use BSA-based dosing, not weight-based, especially in children < 2.5 years old who are at highest risk for frequent relapses 5, 6
Divided dosing: Avoid splitting daily doses; single morning dosing reduces HPA axis suppression by 17% (83% vs 100% suppression rate) 4
Premature dose reduction: Ensure adequate cumulative dose (≥ 3.135 g/m²) during initial episode to reduce risk of frequent relapses 6
Routine infection prophylaxis with steroids: This practice is no longer recommended based on high-quality RCT evidence 2
Prolonging steroids instead of adding steroid-sparing agents: In steroid-dependent or frequently relapsing disease with toxicity, introduce glucocorticoid-sparing agents rather than continuing high-dose or prolonged glucocorticoids 2